Accessibility StatementSkip Navigation EINDHOVEN, Netherlands, Dec. 2, 2025 /PRNewswire/ --Â Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces that it has secured nearly €50m of new financing, consisting of up to €37.5m from the EIB, supported under the European Commission's Invest EU programme, and €10m from existing investors, including EQT, investing from its LSP Health Economics Fund 2, and Invest-NL. The proceeds ...